It has been speculated that b-chemokines play a pivotal role in the development of peripheral nervous system (PNS) disorders characterized by mononuclear cell in®ltration. In experimental allergic neuritis (EAN), an animal model for human Guillain-Barre Â syndrome (GBS) with mononuclear cell in®ltration, we found by quantitative PCR that b-chemokine messages were upregulated during the active stage. Moreover, an increase in the monocyte chemoattractant protein-1 (MCP-1) message was found in the preclinical stage of EAN, suggesting the critical role of MCP-1 for inducing mononuclear cell in®ltrations in this model. Since many cell lineages other than immune cells can produce chemokines, this early upregulation of MCP-1 may be mediated by non-immune cells, probably endothelia or Schwann cells. To date, apart from MCP-1, only RANTES (Regulated on activation, normal T cell expressed and secreted) and macrophage in¯ammatory protein (MIP)-1a have been examined in EAN and found to have similar kinetics of induction. Therefore, understanding the regulation of production of these chemokines as well as mechanisms of inhibiting chemokine/receptor interactions in the PNS may ultimately lead to disease-speci®c therapy for GBS and related demyelinating disorders.
Introduction
The role of chemokines (CK) in peripheral nervous system (PNS) disease is suggested by a number of experimental observations demonstrating leukocyte in®ltration around peripheral nerve ®bers in inammatory neuropathies (Prineas, 1981) . In many PNS diseases, even in non-in¯ammatory PNS diseases like hereditary polyneuropathy, ischemic neuropathy or axonal degeneration after sciatic nerve transection, mononuclear cell in®ltration is involved during the development of pathological changes (Cornblath et al, 1990; Venezie et al, 1995) . Since CK play a pivotal role in leukocyte traf®cking into the CNS (Proost et al, 1996; Baggiolini, 1998) , it has been hypothesized that they play a similar role in the PNS (Adamus et al, 1997; Eng et al, 1996; Godiska et al, 1995; Karpus et al, 1995; Glabinski et al, 1997; Ransohoff et al, 1996) . The PNS is comprised of relatively fewer cell elements than the CNS: Schwann cells, peripheral nerve axons, ®broblasts, endothelia, pericytes and macrophages (Thomas et al, 1993) . Among these cell types, Schwann cells (SC) are possibly the only cell lineage that is unique to the PNS. SC have analogous functions to oligodendrocytes and astrocytes in the CNS: myelination of axons and maintenance of the homeostasis of the neuron, respectively. In addition to these roles, SC also have an immunological role, that of antigen presentation (Gold et al, 1995; Armati and Pollard, 1996) and cytokine production (Armati and Pollard, 1996; Bolin et al, 1995; La Fleur et al, 1996) . Recently, the ability of SC to produce one of the bchemokines, monocyte chemoattractant protein (MCP)-1, in vitro has been shown (Polydefkis et al, 1998) . Moreover, cell lineages other than SC found in the PNS such as ®broblasts and endothelia are a well known cell source for CK. However, to date, expression of only MCP-1, MIP-1a and RANTES has been characterized in the PNS using experimental allergic neuritis (EAN), an animal model for Guillain-Barre Â syndrome. Here we review the present status of CK studies in the PNS, mainly in EAN, and we present our own data concerning bchemokine expression in EAN.
Monocyte chemoattractant protein (MCP)-1 production in experimental allergic neuritis MCP-1, a well characterized b-chemokine, is produced by many cell lineages including monocytes, macrophages, lymphocytes, ®broblasts, endothelia, epithelia (Struyf et al, 1998; Douglas et al, 1997) , and astrocytes (Adamus et al, 1997; Glabinski et al, 1997; Sun et al, 1997) . Its target cells are monocytes, T lymphocytes and NK cells, but not neutrophils (Gu et al, 1997; Schall, 1994; Vaddi et al, 1997) and while a role for MCP-1 in EAE has been proposed (Karpus, 1995) its potential role in experimental allergic neuritis (EAN) has yet to be fully explored. EAN is an animal model for human demyelinating polyneuritis or Guillain-Barre Â syndrome (GBS). EAN, usually induced in Lewis rats, is mediated by Th1 cells and has a monophasic disease course, with spontaneous recovery (Rostami et al, 1985 (Rostami et al, , 1990 . Since the major cell populations seen in the PNS of patients with GBS or rats with EAN are macrophages and lymphocytes (Schmidt et al, 1996; Asbury et al, 1969; Rosen et al, 1992; Zettl et al, 1996) , the involvement of b-chemokines in the development of EAN is strongly suspected.
Recently the kinetics of b-chemokines (MIP-1a, MCP-1 and RANTES) in EAN peripheral nerves has been clari®ed (Spies et al, 1997) . In this study, the messages of b-chemokines were found to increase in concert with the clinical signs of EAN. In our studies, we have assessed the kinetics of bchemokine mRNA expression in rat cauda equina using quantitative competitive RT ± PCR. To do this, we immunized Lewis rats with synthetic peptide SP26 corresponding to the 53 ± 78 amino-acid sequence of the bovine myelin P2 protein to obtain severe clinical disease (Rostami et al, 1990) (Figure  1 ). We found that MCP-1 message increases signi®cantly at day 7 post immunization (p.i.), and that the message remained at a high level during the active disease stage (from days 10 ± 17 p.i.), then returned to a normal level at day 20 p.i. (Figure 2 ). Since the in¯ux of mononuclear in®ltrating cells such as macrophages and lymphocytes begins at the clinical onset of EAN (Rosen et al, 1992; Zettl et al, 1996) , our data suggest that the upregulation of MCP-1 preceding the clinical onset of EAN may attract these mononuclear cells and cause cell in®ltration.
MCP-1 can be produced by SC in vitro upon stimulation by TNF-a or IFN-g, or it may appear within 1 day after nerve transection in vivo (Polydefkis et al, 1998). In addition, MCP-1 production by other cell lineages is stimulated by IL-1 (Schwarz et al, 1997) and IL-6 (Biswas et al, 1998) . Interestingly, MCP-1 expression is suppressed by Th2 cytokines IL-4, IL-10 and IL-13 (Kucharzik et al, 1998) .
These studies raise the question of the relationship between other pro-in¯ammatory cytokines and MCP-1 in the induction of EAN. Most pro-in¯am-matory cytokines are upregulated during the acute stage while anti-in¯ammatory cytokines like TGF-b and IL-10 are upregulated just before clinical recovery starts (Fujioka et al, 1998; Zhu et al, 1998) . Therefore it is possible that MCP-1 is upregulated by pro-in¯ammatory cytokines during the disease-accelerating stage (from preclinical to peak stages), while it is downregulated by antiin¯ammatory cytokines during disease recovery stage. Our data suggest that the production of MCP-1 in the PNS during EAN is strongly regulated by cytokines: speci®cally, upregulation by proin¯ammatory cytokines and downregulation by anti-in¯ammatory cytokines. This hypothesis can explain how MCP-1 is regulated after clinical onset; however, it remains unclear what ®rst triggers the upregulation of MCP-1 before overt mononuclear cell in®ltration. Production of IL-1b from recruiting neuritogenic T cells is a possible explanation since IL-1b is upregulated in the early stage of EAN (Zhu et al, 1998) and can upregulate MCP-1 production (Schwarz et al, 1997) . In EAN, neuritogenic T cells must invade the PNS to initiate tissue-speci®c immune response and demyelination before clinical onset. Once these neuritogenic T cells meet speci®c antigens in the PNS they may produce proin¯ammatory cytokines as well as chemokines. The pro-in¯ammatory cytokines upregulate other proin¯ammatory cytokines and chemokines, increase the permeability of the blood-nerve barrier, activate invading cells, and sometimes cause tissue damage (Rostami et al, 1990) .
Chemokines and peripheral nerve demyelination T Fujioka et al (Lisak et al, 1997) . Upregulated CK attract monocytes/macrophages from the blood stream to the PNS, together with cytokines, resulting in intense in¯ammation in the PNS. This process can be initiated by IL-1b or MCP-1, although the initial signal for this process remains unclear.
As mentioned above, MCP-1 can be produced not only by immune cells but by many other cell lineages found in both the CNS and PNS. While it is assumed that these cells (SC, ®broblasts, endothelia, epithelia, smooth muscle, monocytes, macrophages, lymphocytes and ®broblasts) are the source of b-chemokines in the PNS, this hypothesis has yet to be con®rmed. Thus, important questions concerning the origin and regulation of chemokine expression in the PNS remain, and are the focus of current investigations in our laboratory.
Macrophage in¯ammatory protein (MIP)-1a and
Schwann cells MIP-1a acts as prostaglandin pathway-independent pyrogen in addition to its role in inducing chemotaxis (Minano et al, 1996; Armengol et al, 1997) , suggesting pleiotropic effects. Notably, a suppressor role for MIP-1a against astrocyte growth as well as stimulation of SC growth has been demonstrated (Khan and Wigley, 1994) . These effects on glial cell growth by MIP-1a may be important for the remyelination of peripheral nerve during the recovery stage of EAN. Thus, upregulation of MIP-1a may, as with other b-CKs, cause an in¯ux of mononuclear cells but, unlike other b-CKs, MIP-1a may also help remyelination.
Finally, the b-CK RANTES (Regulated on activation, normal T cell expressed and secreted) may also have a role in EAN. Although its cell source is still unclear, the stimuli for RANTES upregulation and inhibition, and its target cells are similar to those of MCP-1 (Schall, 1994) . In fact, in EAE, the animal model for human multiple sclerosis and the CNS counterpart of EAN, RANTES production is similar to MCP-1 (Glabinski et al, 1997; Godiska et al, 1995; Ransohoff et al, 1996) . In EAN, RANTES shows a similar pattern of secretion as MCP-1 and MIP-1a (Spies et al, 1997) . Thus, evidence suggests a role for multiple b-chemokines in the pathogenesis of EAN and, similar to recent studies in EAE, further analysis of the role of b-chemokines in peripheral demyelination may lead to the rational design of targeted pharmacological therapeutics for demyelinating peripheral nerve disorders (Ransohoff, 1997) .
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This work was supported in part by NIH grant NS-11037. Figure 2 The expression of MCP-1 message in the cauda equina of Lewis rats with experimental allergic neuritis. Total RNA was isolated from caudae equinae removed from rats at different time points, reverse transcribed by Molony Murine Leukemia Virus reverse transcriptase with Oligo (dT) primer. Replicated cDNA was ampli®ed using competitive quantitative PCR (Fujioka et al, 1998) . Message of MCP-1 is expressed as a ratio of b-actin message in the same rats. In this graph, MCP-1 message is shown as an average of four rats in each time point. Bars indicate s.e. Message of MCP-1 increased from days 7 ± 17 p.i. signi®cantly. There was no statistically signi®cant difference within these days (days 7 ± 17 p.i.). MCP-1 message at days 20 and 24 p.i. declined to normal level. Thomas PK, Berthold C-H, Ochoa J (1993 Zettl UK, Gold R, Toyka KV, Hartung HP (1996) . In situ demonstration of T cell activation and elimination in peripheral nervous system during experimental autoimmune neuritis in the Lewis rat. Acta Neuropathol 91: 360 ± 367. Zhu J, Mix E, Link H (1998). Cytokine production and the pathogenesis of experimental autoimmune neuritis and Guillain-Barre Â syndrome. J Neuroimmunol 84: 40 ± 52.
